Advanced Solid Tumors

SEP 8, 2026 · PHASE 1 TRIAL

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

ClinicalTrials.gov

Phase 1 dose-escalation study of a novel combination in advanced solid tumors, terminated after enrolling only 6 participants; no results are posted in this registry record.

AUG 18, 2026 · PHASE 1 TRIAL

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

ClinicalTrials.gov

First-in-human Phase 1 dose-escalation study with no results posted; designed to establish safety, tolerability, and dose recommendations rather than efficacy.

AUG 18, 2026 · PHASE 1 TRIAL

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

ClinicalTrials.gov

Phase 1 trial registration with no results reported; describes planned conduct and safety/dose-finding objectives in an early-stage oncology study.

AUG 17, 2026 · PHASE 1 TRIAL

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

ClinicalTrials.gov

This is a first-in-human Phase 1 trial registration with no results posted; the study is actively recruiting and has not yet reported safety, tolerability, or efficacy outcomes.

AUG 17, 2026 · PHASE 1 TRIAL

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

ClinicalTrials.gov

This is a Phase 1 trial registration with no reported results; the study is actively recruiting and designed to evaluate safety, tolerability, and preliminary antitumor activity in an early-stage drug development program.

AUG 12, 2026 · PHASE 1/2 TRIAL

TT-702 in Patients With Advanced Solid Tumours.

ClinicalTrials.gov

This is a Phase 1/2 trial registry record with no results reported; it describes a planned study of an investigational agent in early development stages.

AUG 11, 2026 · PHASE 1 TRIAL

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

ClinicalTrials.gov

This is a first-in-human Phase 1 dose-escalation study with safety and pharmacokinetic endpoints; no results are posted in this registry record, so the evidence base is not yet available for assessment.

AUG 7, 2026 · PHASE 1 TRIAL

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

ClinicalTrials.gov

Phase 1 trial registration with no results reported; study is active but not yet recruiting, evaluating safety and dosing of a novel AKT1 inhibitor in advanced cancers.